|Articles|March 1, 2007
Pfizer, MediVas team for ophthalmic drug delivery
New York-Pfizer Inc. and MediVas LLC have inked a collaborative agreement to research and develop advanced delivery methods for Pfizer compounds treating ophthalmic diseases.
Advertisement
New York-Pfizer Inc. and MediVas LLC have inked a collaborative agreement to research and develop advanced delivery methods for Pfizer compounds treating ophthalmic diseases.
The deal centers on MediVas' fully biodegradable and biocompatible polymers in combination with Pfizer's ophthalmic compounds to increase therapy adherence and improve eye treatments.
MediVas is based in San Diego. Financial terms were not disclosed.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Last year in glaucoma at EnVision Summit 2025
4
Looking back at the 2025 EnVision Summit
5
























